Regulatory and scientific virtual conference on RNA-based medicines
You should see the live broadcast on pressing the 'play' icon in the video window, or a message stating that we are not currently broadcasting.
To optimise video quality, once the video is playing we recommend clicking on the ‘HD’ symbol in the video window then selecting the '720p' option.
If the video window is blank, or if you experience other difficulties viewing the broadcast, please try connecting directly to the IBM channel.
For technical information about the required network security settings, please see this IBM help page.
For further assistance, please consult the EMA service desk.
The European Medicines Agency (EMA) is organising a virtual conference on 2 February 2023.
The aim of the conference is to promote the development of RNA-based medicines by:
- Identifying scientific and regulatory opportunities and challenges of RNA-based innovative medicines;
- Facilitating dialogue between industry/academia and regulators and raising awareness on scientific and regulatory aspects;
- Identifying gaps in regulatory science.
This initiative addresses Goal 1 (catalysing the integration of science and technology in medicines development) of the EMA Regulatory Science Strategy to 2025.
The conference focuses on emerging RNA technologies beyond vaccines.
RNA for gene editing and primary prevention of infectious diseases is not within the scope of this event.
The event is open to all stakeholders, registration enables active participation. The event will be broadcast and recorded, and the videos will be made available after the event.
- Registration is now closed.
Broadcast will be accessible on the day of the event for participants whose registration in Webex was not successful.